Bent Frandsen

Bent Frandsen, listed as chief executive, has filed trades across 2 companies (mainly through Finansinspektionen), most often in ExpreS2ion Biotech Holding AB and ExpreS2ion Biotech Holding AB (EXPRS2). The record holds 13 filings, for trades running from 14 July 2020 to 9 October 2026.

Market trades split into 5 purchases (€47k) and 1 sale (€43). Taken together, the purchases exceed the sales by €47k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants. 2026 to date brings 3 purchases and 1 sale.

A typical purchase (the median) is worth €1,252. As a share of market capitalisation, the median purchase stands at 0.042%, based on 3 purchases. 1 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 9 October 2026, the filings show an open-market purchase worth €977 in ExpreS2ion Biotech Holding AB. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.